Weekly shot aims to stop bleeding in rare blood disorder
NCT ID NCT07273721
Summary
This study is testing a new drug called BT200 for adults with type 2B von Willebrand disease, a rare inherited bleeding disorder. Participants will give themselves a weekly injection of either the drug or a placebo for four weeks, then switch after a break. The main goal is to see if BT200 can safely increase important blood clotting factors and reduce the number of bleeding episodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD), TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of Vienna, Department of Clinical Pharmacology
RECRUITINGVienna, Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.